Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UQ07
UPID:
MOK_HUMAN
Alternative names:
MOK protein kinase; Renal tumor antigen 1
Alternative UPACC:
Q9UQ07; B2R6Z4; B7Z7P6; E7ER76; E7ERR8; Q92790; Q93067
Background:
MAPK/MAK/MRK overlapping kinase, also known as MOK protein kinase or Renal tumor antigen 1, is a pivotal enzyme capable of phosphorylating various substrates and executing autophosphorylation. It plays a crucial role in regulating cilium length through cAMP and mTORC1 signaling pathways.
Therapeutic significance:
Understanding the role of MAPK/MAK/MRK overlapping kinase could open doors to potential therapeutic strategies.